Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extensionJ Neurol 2023 Oct 31;[EPub Ahead of Print], L Kappos, A Traboulsee, DKB Li, A Bar-Or, F Barkhof, X Montalban, D Leppert, A Baldinotti, HM Schneble, H Koendgen, A Sauter, Q Wang, SL Hauser
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.